Stock Price Movements of Various Companies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MRNA?
Source: CNBC
- Acadia Healthcare Stock Surge: Acadia Healthcare's stock rose 10% after investor David Einhorn announced his purchases, reflecting market optimism about the new management's ability to enhance performance, which could improve future profitability.
- Vertiv's Upbeat Guidance: Vertiv's stock jumped nearly 20% due to its optimistic guidance for 2026, with orders accelerating significantly in Q4, surpassing Wall Street expectations and indicating strong demand in the data center market.
- Unity Software's Downgrade: Unity Software's shares fell nearly 30% after issuing a first-quarter revenue outlook between $480 million and $490 million, below analysts' expectations of $492.1 million, raising concerns about its future growth prospects.
- Smurfit WestRock Order Improvement: Smurfit WestRock's stock soared over 10% after revealing improved product orders in late December, with expectations of reaching $7 billion in profits by 2030, highlighting its long-term growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 43.930
Low
17.00
Averages
32.47
High
63.00
Current: 43.930
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna Shares Surge Following FDA's Start of Flu Vaccine Review
- FDA Review Announcement: The U.S. Food and Drug Administration (FDA) will begin reviewing Moderna's investigational seasonal flu vaccine.
- Company Statement: Moderna announced the initiation of the review on Wednesday.
See More
Moderna's mRNA-1010 Marketing Application Accepted by FDA
- FDA Acceptance: The U.S. FDA has accepted Moderna's marketing application for mRNA-1010, marking a significant advancement in the company's vaccine development, with a target action date set for August 5, 2026, thereby laying the groundwork for future market expansion.
- Revised Application Pathway: During a Type A meeting with the FDA, Moderna proposed an amended biologics license application (BLA) that includes an age-dependent regulatory pathway and a post-marketing requirement for additional trials in older adults, demonstrating the company's commitment to regulatory compliance.
- Market Expectations: Moderna plans to launch mRNA-1010 for adults aged 50 and older in the 2026/2027 flu season, a strategy that not only addresses the demand for flu vaccines among the elderly but also has the potential to enhance the company's market share and brand influence.
- Stock Price Recovery: Following the FDA's acceptance of the application, Moderna's shares gained in premarket trading, reflecting investor optimism about the company's future growth potential, especially after facing pressure from last week's FDA refusal-to-file letter.
See More
Moderna's COVID-19 Vaccine mNEXSPIKE Receives EU Marketing Authorization
- EU Marketing Authorization: Moderna's COVID-19 vaccine mNEXSPIKE has received marketing authorization from the European Commission for individuals aged 12 and older, marking the company's third product approved in the EU, thereby enhancing its competitive position in the global vaccine market.
- Clinical Trial Results: In a randomized, controlled Phase 3 trial involving approximately 11,400 participants, mNEXSPIKE demonstrated a 9.3% higher relative vaccine efficacy compared to Spikevax, with a 13.5% increase in adults aged 65 and older, providing strong support for its market launch.
- Safety Profile: The safety profile of mNEXSPIKE is comparable to Spikevax, with fewer local reactions and similar systemic reactions, and the most commonly reported adverse effects include injection site pain, fatigue, headache, and myalgia, indicating good tolerability.
- Market Outlook: Moderna has already secured regulatory approval for mNEXSPIKE in the U.S., Canada, and Australia, and is pursuing additional market authorizations worldwide, which is expected to drive future revenue growth for the company.
See More
Delaware Judge Dismisses Key Defenses in Moderna Patent Case
- Patent Defense Dismissed: Delaware Judge Joshua Wolson has dismissed two key defenses raised by Moderna in its ongoing patent litigation against Arbutus Biopharma, particularly the defense based on obviousness, stating that Moderna failed to raise these claims in prior inter partes review, thus barring them from asserting them in this case.
- Impact of IPR Estoppel: The judge emphasized that IPR estoppel prevents defendants from raising obviousness claims made in an IPR proceeding, which Moderna already lost, further weakening its position in the litigation.
- Issue Preclusion Defense Fails: Moderna's other defense, based on issue preclusion, argued that the patent subject matter was not actually invented by Arbutus; however, the judge noted that Moderna failed to demonstrate prior conception by another, with its own expert conceding that an Arbutus scientist encapsulated mRNA in lipid nanoparticles before Moderna did.
- Enablement Defense Allowed: Despite facing significant setbacks, the judge has allowed Moderna's enablement defense to proceed, asserting that enablement ensures adequate disclosure of the claimed invention and prevents claims broader than what is disclosed, potentially providing Moderna with a continued avenue for defense.
See More
U.S. Stocks Close Mixed, Apple Shares Rise on Product Launch News
- Market Performance Fluctuates: On Tuesday, the S&P 500 rose by 0.10%, the Dow Jones increased by 0.07%, while the Nasdaq 100 fell by 0.13%, indicating a mixed market recovery from early losses, with the Nasdaq 100 hitting a 2.75-month low, reflecting investor caution towards tech stocks.
- Apple Product Launch Boost: Apple shares surged over 3% after announcing a product launch on March 4, with several new devices expected in the coming weeks, which not only boosted Apple's market performance but also generated positive sentiment across the tech sector.
- Airline Stocks Rally: Airline stocks showed strong performance on Tuesday, led by a 6% increase in Southwest Airlines after UBS upgraded its rating from neutral to buy with a price target of $73, which not only enhanced the overall performance of airline stocks but also contributed to a more optimistic market outlook.
- Mixed Economic Data: The U.S. February NAHB housing market index unexpectedly fell to a 5-month low of 36, below the expected 38, while the February Empire manufacturing survey slightly declined to 7.1, indicating uncertainty in economic recovery, as the market remains focused on upcoming corporate earnings and economic news.
See More
Shopify's Earnings Cause Market Whiplash; Moderna's Vaccine Rejected by FDA
- Shopify Earnings Volatility: Shopify's stock surged 13% in pre-market trading before its fourth-quarter earnings report, but plummeted 6% by the end of the day after management's conference call raised concerns about future growth, particularly regarding the concept of 'agentic commerce' that unsettled investors.
- Strong Revenue Growth: The company reported a 31% year-over-year revenue growth, maintaining the same rate as last year, with merchandise volume through its platform increasing by 29%, indicating ongoing expansion in the e-commerce sector; however, the missed EPS expectations led to a negative market reaction.
- Moderna Vaccine Approval Setback: The FDA's refusal to review Moderna's new flu vaccine marks the second regulatory challenge within a year, potentially jeopardizing the company's future MRNA technology developments, particularly for vaccines targeting cancer and rare diseases.
- Increased Cash Flow Pressure: Moderna faces significant cash burn, relying on revenue from COVID vaccines to fund its R&D; the FDA's rejection may force the company to reassess its development strategy in the current regulatory climate.
See More
Moderna Shares Surge Following FDA's Start of Flu Vaccine Review
- FDA Review Announcement: The U.S. Food and Drug Administration (FDA) will begin reviewing Moderna's investigational seasonal flu vaccine.
- Company Statement: Moderna announced the initiation of the review on Wednesday.
See More
Moderna's mRNA-1010 Marketing Application Accepted by FDA
- FDA Acceptance: The U.S. FDA has accepted Moderna's marketing application for mRNA-1010, marking a significant advancement in the company's vaccine development, with a target action date set for August 5, 2026, thereby laying the groundwork for future market expansion.
- Revised Application Pathway: During a Type A meeting with the FDA, Moderna proposed an amended biologics license application (BLA) that includes an age-dependent regulatory pathway and a post-marketing requirement for additional trials in older adults, demonstrating the company's commitment to regulatory compliance.
- Market Expectations: Moderna plans to launch mRNA-1010 for adults aged 50 and older in the 2026/2027 flu season, a strategy that not only addresses the demand for flu vaccines among the elderly but also has the potential to enhance the company's market share and brand influence.
- Stock Price Recovery: Following the FDA's acceptance of the application, Moderna's shares gained in premarket trading, reflecting investor optimism about the company's future growth potential, especially after facing pressure from last week's FDA refusal-to-file letter.
See More
Moderna's COVID-19 Vaccine mNEXSPIKE Receives EU Marketing Authorization
- EU Marketing Authorization: Moderna's COVID-19 vaccine mNEXSPIKE has received marketing authorization from the European Commission for individuals aged 12 and older, marking the company's third product approved in the EU, thereby enhancing its competitive position in the global vaccine market.
- Clinical Trial Results: In a randomized, controlled Phase 3 trial involving approximately 11,400 participants, mNEXSPIKE demonstrated a 9.3% higher relative vaccine efficacy compared to Spikevax, with a 13.5% increase in adults aged 65 and older, providing strong support for its market launch.
- Safety Profile: The safety profile of mNEXSPIKE is comparable to Spikevax, with fewer local reactions and similar systemic reactions, and the most commonly reported adverse effects include injection site pain, fatigue, headache, and myalgia, indicating good tolerability.
- Market Outlook: Moderna has already secured regulatory approval for mNEXSPIKE in the U.S., Canada, and Australia, and is pursuing additional market authorizations worldwide, which is expected to drive future revenue growth for the company.
See More
Delaware Judge Dismisses Key Defenses in Moderna Patent Case
- Patent Defense Dismissed: Delaware Judge Joshua Wolson has dismissed two key defenses raised by Moderna in its ongoing patent litigation against Arbutus Biopharma, particularly the defense based on obviousness, stating that Moderna failed to raise these claims in prior inter partes review, thus barring them from asserting them in this case.
- Impact of IPR Estoppel: The judge emphasized that IPR estoppel prevents defendants from raising obviousness claims made in an IPR proceeding, which Moderna already lost, further weakening its position in the litigation.
- Issue Preclusion Defense Fails: Moderna's other defense, based on issue preclusion, argued that the patent subject matter was not actually invented by Arbutus; however, the judge noted that Moderna failed to demonstrate prior conception by another, with its own expert conceding that an Arbutus scientist encapsulated mRNA in lipid nanoparticles before Moderna did.
- Enablement Defense Allowed: Despite facing significant setbacks, the judge has allowed Moderna's enablement defense to proceed, asserting that enablement ensures adequate disclosure of the claimed invention and prevents claims broader than what is disclosed, potentially providing Moderna with a continued avenue for defense.
See More
U.S. Stocks Close Mixed, Apple Shares Rise on Product Launch News
- Market Performance Fluctuates: On Tuesday, the S&P 500 rose by 0.10%, the Dow Jones increased by 0.07%, while the Nasdaq 100 fell by 0.13%, indicating a mixed market recovery from early losses, with the Nasdaq 100 hitting a 2.75-month low, reflecting investor caution towards tech stocks.
- Apple Product Launch Boost: Apple shares surged over 3% after announcing a product launch on March 4, with several new devices expected in the coming weeks, which not only boosted Apple's market performance but also generated positive sentiment across the tech sector.
- Airline Stocks Rally: Airline stocks showed strong performance on Tuesday, led by a 6% increase in Southwest Airlines after UBS upgraded its rating from neutral to buy with a price target of $73, which not only enhanced the overall performance of airline stocks but also contributed to a more optimistic market outlook.
- Mixed Economic Data: The U.S. February NAHB housing market index unexpectedly fell to a 5-month low of 36, below the expected 38, while the February Empire manufacturing survey slightly declined to 7.1, indicating uncertainty in economic recovery, as the market remains focused on upcoming corporate earnings and economic news.
See More
Shopify's Earnings Cause Market Whiplash; Moderna's Vaccine Rejected by FDA
- Shopify Earnings Volatility: Shopify's stock surged 13% in pre-market trading before its fourth-quarter earnings report, but plummeted 6% by the end of the day after management's conference call raised concerns about future growth, particularly regarding the concept of 'agentic commerce' that unsettled investors.
- Strong Revenue Growth: The company reported a 31% year-over-year revenue growth, maintaining the same rate as last year, with merchandise volume through its platform increasing by 29%, indicating ongoing expansion in the e-commerce sector; however, the missed EPS expectations led to a negative market reaction.
- Moderna Vaccine Approval Setback: The FDA's refusal to review Moderna's new flu vaccine marks the second regulatory challenge within a year, potentially jeopardizing the company's future MRNA technology developments, particularly for vaccines targeting cancer and rare diseases.
- Increased Cash Flow Pressure: Moderna faces significant cash burn, relying on revenue from COVID vaccines to fund its R&D; the FDA's rejection may force the company to reassess its development strategy in the current regulatory climate.
See More
